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Abstract
 
Interleukin (IL) 23 is a heterodimeric cytokine composed of a p19 subunit and the p40 subunit
of IL-12. IL-23 affects memory T cell and inflammatory macrophage function through engagement
of a novel receptor (IL-23R) on these cells. Recent analysis of the contribution of IL-12 and
IL-23 to central nervous system autoimmune inflammation demonstrated that IL-23 rather
than IL-12 was the essential cytokine. Using gene-targeted mice lacking only IL-12 (p35
 

 
/
 

 
)
or IL-23 (p19
 

 
/
 

 
), we show that the specific absence of IL-23 is protective, whereas loss of IL-12
exacerbates collagen-induced arthritis. IL-23 gene-targeted mice did not develop clinical signs
of disease and were completely resistant to the development of joint and bone pathology.
Resistance correlated with an absence of IL-17–producing CD4
 

 
 T cells despite normal induction
of collagen-specific, interferon-
 

 
–producing T helper 1 cells. In contrast, IL-12–deficient
p35
 

 
/
 

 
 mice developed more IL-17–producing CD4
 

 
 T cells, as well as elevated mRNA
expression of proinflammatory tumor necrosis factor, IL-1
 

 
, IL-6, and IL-17 in affected tissues
of diseased mice. The data presented here indicate that IL-23 is an essential promoter of end-
stage joint autoimmune inflammation, whereas IL-12 paradoxically mediates protection from
autoimmune inflammation.
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Introduction
 
IL-12 and IL-23 share a common p40 subunit, yet they
comprise unique p35 and p19 subunits, respectively (1).
Studies have defined IL-12 as an important factor for the dif-
ferentiation of naive T cells into IFN-
 

 
–producing Th1 cells
(2). Furthermore, gene-targeted mice, which specifically
lack IL-12 signaling capabilities through IL-12R-
 

 
2 muta-
tions (3) or deletion of the IL-12p35 gene (4), exhibit
heightened susceptibility to bacterial infections. This is prob-
ably due to poor IFN-
 

 
 production in these mice, given the
important role IFN-
 

 
 plays in antimicrobial immunity (5).
Thus, an important role for IL-12 in the generation of Th1
cell–mediated immunity has been well established.
The role for IFN-
 

 
 during induction of organ-specific
autoimmune diseases is less clear (6–9), and the absolute
requirement for IL-12–mediated Th1 responsiveness in au-
toimmune inflammation has been questioned in several recent
papers (10–12). Collagen-induced arthritis (CIA), a rodent
model of the human disease rheumatoid arthritis, is induced
by immunization with heterologous type II collagen (CII)
emulsified in CFA (13). Development of CIA is dependent
on both cell-mediated and humoral responses (14) and is
characterized by cellular infiltration and synovitis of the
joints, resulting in severe swelling of the paws and progressive
destruction of bone and cartilage. Loss of IFN-
 

 
 signaling
has been reported to increase severity of CIA (7, 8).
To determine the relative roles of IL-12 and IL-23 in
the establishment and maintenance of autoimmune inflamma-
tion, we have analyzed the production of inflammatory
cytokines and collagen-specific antibodies after the induction
of CIA in p19
 

 
/
 

 
 (IL-23–deficient) mice, p35
 

 
/
 

 
 (IL-12–
deficient) mice, and p40
 

 
/
 

 
 (IL-12– and IL-23–deficient)
mice. Consistent with the dominant role for IL-23 in central
nervous system (CNS) autoimmune inflammation (12),
IL-23–deficient mice were resistant to CIA. In contrast,
IL-12–deficient mice showed enhanced joint swelling and
joint pathology, and, within affected joint tissue, increased
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mRNA levels encoding for inflammatory mediators, such
as IL-17 and TNF. Absence of IL-12, alone (p35
 

 
/
 

 
) or in
combination with IL-23 (p40
 

 
/
 

 
 mice), also resulted in
increased anticollagen antibody production, but decreased
mRNA encoding for IFN-
 

 
 in joints of CIA-affected IL-
12–deficient mice relative to arthritic WT mice, an out-
come consistent with a key role for IL-12 in IFN-
 

 
 induc-
tion. An increased number of IL-17–producing CD4
 

 
 T
cells was evident in cultured draining LN (DLN) cells ob-
tained from IL-12–deficient mice. Significantly, these po-
tentially pathogenic T cells were absent in mice lacking
IL-23. Thus, as in CNS inflammation (12), IL-23 is an es-
sential mediator of joint inflammation, with at least one of
its activities being to support production of IL-17–produc-
ing CD4
 

 
 T cells. In contrast, IL-12 is not critical for dis-
ease generation, but is the key factor in IFN-
 

 
 induction.
IL-12 appears to regulate the inflammatory process, possi-
bly through the induction of IFN-
 

 
.
 
Materials and Methods
 
Mice. 
 
IL-12p35
 

 
/
 

 
, IL-12p40
 

 
/
 

 
, and WT control mice on
the C57BL/6 background were obtained from the Jackson Lab-
oratory. IL-23p19
 

 
/
 

 
 mice and WT B6 
 

 
 129 F2 controls have
been described previously (12). p19
 

 
/
 

 
 mice on the C57BL/6
background were used in intracellular cytokine detection exper-
iments.
 
CIA. 
 
CIA was induced in male and female C57BL/6 and
B6 
 

 
 129 F2 mice aged 8–16 wk and clinically assessed as de-
scribed previously (15). Mice were killed at day 42 after primary
immunization; the rear paws were removed, fixed, decalcified in
Cal-EX II (Fisher Scientific), and processed for paraffin embed-
ding; and the sections were cut and stained with hematoxylin
and eosin.
 
T Cell Proliferation and Cytokine Production. 
 
For T cell prolif-
eration assay, cells were stimulated with 0–200 
 

 
g/ml denatured
chicken CII (boiled for 10 min) and cultured for 72 h with
[
 
3
 
H]thymidine addition during the final 18 h. For cytokine mea-
surement, cells were stimulated with 100 
 

 
g/ml denatured CII
for 72 h and supernatants were assayed for IFN-
 

 
 and IL-4 by
ELISA (R&D Systems).
 
ELISA Detection of CII-specific Antibodies. 
 
Mice were bled
and serum was prepared for determination of serum CII-specific
Ab levels by ELISA. Samples were added to CII-coated 96-well
plates (Chondrex Inc.) and incubated overnight. Horseradish per-
oxidase–conjugated goat anti–mouse Ig (H 
 
 
 
L; total Ig), IgG
 
1
 
,
or IgG
 
2a
 
 were applied to determine the isotype of CII-specific an-
tibodies. The quantity of CII-specific Ab detected is expressed as
OD
 
490
 
 readings minus the relevant blank.
 
Gene Expression Analysis. 
 
RNA was extracted from hind
paws of mice, cDNA was prepared, and mRNA levels were
quantitated as described previously (16).
 
DLN Cultures for Intracellular IL-17 and IFN-
 

 
 Detection.
 
DLNs were harvested from WT, p19
 

 
/
 

 
, p35
 

 
/
 

 
, and p40
 

 
/
 

 
mice (all on C57BL/6 background). For intracellular staining,
DLN cells were initially stimulated with 50 ng/ml PMA and 500
ng/ml ionomycin (Sigma-Aldrich) in the presence of GolgiPlug™
for 3 h and stained with FITC-conjugated anti-CD4. Samples
were washed, fixed, permeabilized with Cytofix/Cytoperm™
buffer, and stained with PE- or allophycocyanin-conjugated anti–
IL-17 and anti–IFN-
 

 
. All antibodies and buffers unless otherwise
stated were purchased from BD Biosciences.
Figure 1. IL-23, and not IL-12,
is required for induction of CIA.
(A) Cumulative incidence and
the mean clinical score of mice
that developed clinical disease are
plotted against days after primary
immunization with CII/CFA.
(B) Disease incidence (number
of diseased mice/total mice in
group), disease severity (median
maximum disease score attained
and range of clinical scores), and
mean day of onset of clinical
disease are shown for mice of all
genotypes. a, Only mice that de-
veloped clinical signs of disease
were analyzed. N/A, not appli-
cable. (C) Histopathology of
decalcified paws at day 42 after
primary CII immunization from
WT, p35/, and p19/ mice.
Hematoxylin and eosin staining
of tarsal joints from both WT
and p35/ mice frequently
showed severe pathology with
articular cartilage erosion (),
synovial inflammation (S), and
pannus (P) formation. p19/
joints showed no pathology,
characterized by smooth, intact
articular cartilage () and no
cellular infiltrate in the joint space
(J). Original magnification, 100.
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Results and Discussion
 
IL-23 Rather Than IL-12 Is Essential for Development of
Joint Autoimmune Inflammation. 
 
To study the differential
functions of IL-12 and IL-23 in joint autoimmune inflam-
mation, we compared susceptibility of mice lacking only
IL-23 (p19
 

 
/
 

 
), only IL-12 (p35
 

 
/
 

 
), or both cytokines
(p40
 

 
/
 

 
) to CIA. Overall incidence of disease was similar
in WT C57BL/6 and B6 
 

 
 129 F2 mice (Fig. 1, A and B,
 

 
50%) as reported previously (17). In contrast, mice spe-
cifically lacking IL-23 (p19
 

 
/
 

 
) and those animals lacking
both IL-12 and IL-23 (p40
 

 
/
 

 
) were resistant to CIA in-
duction (Fig. 1, A and B). Histological examination of
joints revealed no pathology in p40
 

 
/
 

 
 (reference 18; not
depicted) and p19
 

 
/
 

 
 mice (Fig. 1 C). Unexpectedly, mice
specifically lacking only IL-12 (p35
 

 
/
 

 
) were highly sus-
ceptible to CIA with 80% of mice developing clinical signs
of disease (Fig. 1, A and B). Histologically, disease was in-
distinguishable from that of similarly affected WT animals
(Fig. 1 C). However, disease severity (Fig. 1 B) appeared to
be more intense in p35
 

 
/
 

 
 mice (median clinical score of
mice with disease 
 

 
 6; 12 out of 15 mice developed dis-
ease) compared with WT C57BL/6 mice (median clinical
score of mice with disease 
 

 
 4; 10 out of 18 mice devel-
oped disease). Disease recovery was also delayed in mice
lacking only IL-12 (Fig. 1 A). Thus, IL-23, but not IL-12,
is necessary for the development of joint autoimmune in-
flammation, and the absence of IL-12 may result in a more
severe disease.
 
Reduced IFN-
 

 
 and Elevated CII-specific Antibodies in IL-
12–deficient Mice. 
 
CIA development is dependent on
both T and B cell responses (14, 19), and the nature of the
T cell response can have an important impact in initiating
CIA (20). T cell development was first examined by CII-
specific proliferation, and cytokine production in DLN
cells was taken from mice 10 d after immunization with
CII/CFA. WT C57BL/6, WT B6 
 

 
 129 F2, p19
 

 
/
 

 
,
p35
 

 
/
 

 
, and p40
 

 
/
 

 
 mice had similar CII-specific prolifera-
tive responses, regardless of susceptibility to CIA (Fig. 2 A),
indicating that induction of CII-reactive T cells did not de-
pend on either IL-12 or IL-23. DLN cells from p19
 

 
/
 

 
mice secreted WT levels of IFN-
 

 
, but undetectable levels
of IL-4, in response to CII stimulation, indicating that clas-
sical Th1 cells were induced in these mice (Fig. 2 B). In
contrast, DLN cells from p40
 

 
/
 

 
 mice exhibited a Th2
phenotype with low IFN-
 

 
 and high IL-4 levels. DLN
cells from highly CIA susceptible p35
 

 
/
 

 
 mice produced
low levels of IFN-
 

 
 (Fig. 2 B) in accordance with the
known role for IL-12 in driving this cytokine (2, 21), yet
did not produce IL-4, consistent with small amounts of
IFN- seen in these cultures (Fig. 2 B). Our ongoing stud-
ies, as well as recent published work (22), indicate that
mouse IL-23 does not induce IFN- production in T cells,
but rather induces TNF and IL-17 (see the IL-23 Promotes
the Development...section).
p19/ mice generated a lower CII-specific antibody
response compared with WT B6  129 F2 controls, sug-
gesting that their resistance to CIA may be due in part to
impaired humoral responses (Fig. 2 C). Thus, even
though p19/ mice have normal T cell response with
normal capacity to produce IL-12 and IFN- (Fig. 2 B;
reference 12), their ability to elicit collagen-specific au-
Figure 2. Type II collagen
(CII)–specific T and B cell re-
sponses in IL-23– and IL-12–
deficient mice. (A) Normal CII-
specific T cell proliferation for
both IL-23– and IL-12–deficient
mice from DLN cells taken day
10 after CII/CFA immunization
(n  3–4/group) were cultured
individually in triplicate. Data
show the mean proliferative re-
sponse of DLN cells for each
genotype 	 SEM. (B) DLN cells
(day 10 after CII immunization)
from individual mice were cul-
tured and assayed as described in
Materials and Methods. Data
represent the mean response of
3–4 mice 	 SEM. (C) Divergent
humoral responses by p19/
mice versus p35/ and p40/
mice. Sera levels of CII-specific
total Ig and IgG1 at day 42 after
primary CII immunization (n 
5/group) were determined by
ELISA. Differences in Ig levels
between relevant groups are indi-
cated by p-values as determined
by the unpaired Student’s t test.
Data represent the mean 	 SEM.
 o
n
 O
ctober 13, 2015
jem.rupress.org
D
ow
nloaded from
 
Published December 8, 2003
IL-23 and IL-12 Activities in Arthritis1954
toantibodies is impaired. By contrast, p35/ mice had in-
creased CII-specific total Ig and IgG1 levels (Fig. 2 C)
compared with WT C57BL/6 mice, suggesting that spe-
cific absence of IL-12 leads to increased autoantibody pro-
duction. At this stage, it is not known whether this has a
causative role in contributing to increased disease severity
in p35/ mice. Low and comparable levels of CII-spe-
cific IgG2a were detected in WT C57BL/6, WT B6 
129 F2, p19/, p35/, and p40/ mice (unpublished
data). p40/ mice also exhibited increased CII-specific
total Ig and IgG1, even though these mice were com-
pletely resistant to CIA. This result is in contrast to others
that have reported reduced CII-specific antibody re-
sponses in p40/ mice backcrossed onto the DBA/1
background (18), and in anti–IL-12p40–treated DBA/1
mice immunized to induce CIA (23). This may be due to
differences in mouse strains used in the studies. It has also
been shown in several infectious disease models that p40/
mice on a C57BL/6 background produce dramatically
elevated levels of IgG1 (24) and IgE (25). Overall, the re-
sults suggest that IL-12 may be an important regulator of
autoantibody responses, especially of those isotypes com-
monly associated with a Th2 or allergic phenotype. Sig-
nificantly, the presence of high CII-specific antibody lev-
els in p40/ mice was not sufficient to induce arthritis in
the absence of IL-23 and IL-12.
IL-23 Is Required for Induction of Joint Inflammatory Media-
tors, Including IL-17 and TNF. To further analyze the
means through which IL-23 deficiency mediates its protec-
tion in CIA, and in contrast, how the absence of IL-12 re-
sults in more severe disease, we adopted a gene expression
strategy. At day 42 after primary immunization with CII/
CFA (1 wk after peak of disease in WT mice), IFN-
mRNA levels were elevated above naive levels only in WT
paws (Fig. 3 A) and in accordance with this, the IFN-–
inducible chemokines, monokine induced by IFN- (Mig)
and IFN-–inducible protein 10 (IP-10; reference 26)
were also elevated only in WT samples (Fig. 3 A). Notably,
these factors were not elevated in p35/ samples. Also, al-
though IL-23–deficient mice generate a normal antigen-
specific Th1 response characterized by IFN- production
by DLN cells (Fig. 2 B), this response does not develop in
the joints, as indicated by the absence of mRNA encoding
both IFN- and chemokines induced by IFN- (Fig. 3 A).
mRNA levels for the proinflammatory cytokines IL-1,
IL-6, TNF, and IL-17, as well as a range of chemokines in-
cluding MIP-1 (Fig. 3 B), MIP-1
, and MCP-6 (not de-
picted) remained elevated in WT and p35/ paws at day
42, but were not elevated above unimmunized WT (naive)
levels in p19/ and p40/ paws (Fig. 3 B). These factors,
levels of IL-1 and IL-6 in particular, were substantially
higher in paws of p35/ mice, which is indicative of the
more chronic disease in these animals relative to arthritic
WT controls (Fig. 3 B). Nitric oxide synthase 2 gene ex-
pression, which is associated with activated macrophages (a
major component of the synovial cellular infiltrate), was also
elevated in p35/ mice relative to arthritic WT animals
(Fig. 3 B). These results suggest that the specific absence of
Figure 3. Reduced IFN-, but
elevated inflammatory cytokine
and chemokine expression by
p35/ mice. Cytokine and che-
mokine mRNA levels in hind
paws day 42 after primary CII/
CFA immunization were deter-
mined by quantitative real-time
PCR and expressed in units rela-
tive to ubiquitin mRNA levels.
(A) mRNA expression levels for
IFN- and the IFN-–inducible
chemokines IP-10 and Mig. (B)
mRNA expression of genes en-
coding proinflammatory factors.
RNA from 3 to 5 individual paw
samples for each genotype were
pooled for analysis, except for
IFN- and IL-17, where the
data represent the mean 	 SEM;
n  3. The abundance of mRNA
encoding IFN- and IL-17 were
very low and, hence, were con-
firmed using expression data
from individual mice. (Naive)
Paws from unimmunized mice.
WT samples, both inflamed and
naive, consist of pooled RNA
from both C57BL/6 and B6 
129 F2 mice.
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IL-12, associated with reduced levels of IFN- and increased
expression of IL-1, IL-6, IL-17, TNF, and nitric oxide
synthase 2, exacerbates autoimmune joint inflammation.
IL-23 Promotes the Development of IL-17–producing T
Cells. IL-17 is a potent proinflammatory cytokine pro-
duced by PBMCs/T cells and by cells isolated from syn-
ovial fluid of rheumatoid arthritis patients (27). To deter-
mine whether there is a correlation between IL-23 and the
development of IL-17–producing cells, we analyzed DLN
cell cultures derived from mice inoculated s.c. with CFA
(Fig. 4). Ex vivo analysis of DLN cells from WT C57BL/6
mice showed two relatively discrete populations of IFN-
and IL-17–producing CD4 T cells. In contrast, p19/
mice (C57BL/6 background) showed an absence of IL-17–
producing CD4 cells, as did p40/ mice, which also lack
IL-23 (Fig. 4). Identical results were observed with p19/
versus WT mice on the B6  129 F2 background (unpub-
lished data). IL-12–deficient (p35/) mice showed ele-
vated numbers of IL-17–producing T cells relative to WT
controls. DLN cells from WT and p19/ mice both pro-
duced IFN- (Fig. 4), which is consistent with their ability
to produce CII-specific IFN- (Fig. 2 B). Culture of DLN
cells for 5 d in the presence of IL-12 caused skewing of
CD4 T cells toward IFN- production. Conversely, cul-
ture with IL-23 skewed toward IL-17 production, and this
effect was especially dramatic in p35/ and p40/ ani-
mals in which IFN- production is minimal (Fig. 4). Pre-
liminary studies indicate that IFN- neutralization in vitro
enables outgrowth of IL-17–producing CD4 T cells (un-
published data). These results indicate that IL-23 promotes
the development of IL-17–producing cells, whereas IL-12
drives IFN- production.
We have shown previously that IL-23 is required for
CNS autoimmunity (12), and here we show that IL-23 is
also essential in joint autoimmune inflammation and, there-
fore, possibly other organ-specific autoimmune diseases.
Thus, IL-23, but not IL-12, is necessary for disease devel-
opment. Moreover, the absence of IL-12 results in more
severe disease, reflected in elevated and prolonged expres-
sion of proinflammatory cytokines such as IL-1, IL-6, IL-
17, and TNF (Fig. 3 B). These results are in agreement
with other papers (10–12) demonstrating that mice selec-
tively lacking only IL-12 (p35/ mice) or IL-12R, the
specific IL-12 signaling chain (28), exhibit increased sever-
ity of experimental autoimmune encephalomyelitis com-
pared with WT animals.
Together, these studies are consistent with the view that
IL-12, on the one hand, is a key factor driving Th1 re-
sponses and IFN- production in the initial phases of an
immune response; on the other hand, IL-12 may play a
subsequent immunoregulatory role in late-stage inflamma-
tion at a point when IL-23 strongly supports the inflamma-
Figure 4. IL-23 promotes the production of IL-17,
which is regulated by the IL-12 pathway. Intracellular
detection of IFN- and IL-17 protein by CD4 T
cells from DLN cells at day 10 after CFA immuni-
zation. Cells were either analyzed immediately after
isolation (ex vivo) or after 5 d of culture in the
presence of rIL-12 or rIL-23, both at 10 ng/ml. All
plots are gated on live CD4 T cells and are repre-
sentative of four separate experiments.
Figure 5. A model proposing the respective roles of IL-12/IFN- and
IL-23 in T cell-priming events versus end-stage autoimmune inflamma-
tion. The precise mechanism through which IL-12/IFN- may down-
regulate the magnitude of the inflammatory response (i.e., reducing IL-17
production) remains to be defined. It is recognized that IFN- may have
dual roles during late-stage inflammation (i.e., antiinflammatory actions
through termination of activated T cell responses [references 9, 29] while
also stimulating macrophage function [reference 5]). a, The IL-23R is
present on CD4 CD45RBlo “memory” T cells (30), but this cell phe-
notype may also include activated CD4 T cells that are not strictly
memory T cells.
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tory process (Fig. 5). Interplay between IL-23 and IL-17
production may be a critical immune pathway, potentially
regulated via an IL-12–induced IFN- pathway (Figs. 4
and 5; reference 22). Therefore, specific therapeutic block-
ade of IL-23 (rather than IL-12 neutralization) may provide
a preferred approach for the treatment of a range of inflam-
matory autoimmune diseases.
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